Skip to main content

Malignant Pleural Effusion

9
Pipeline Programs
13
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 11 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Abnoba
AbnobaGermany - Niefern-Oeschelbronn
1 program
1
Abnoba Viscum F 20mgPhase 31 trial
Active Trials
NCT02191540Completed68Est. May 2013
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
tumor derived microparticlesPhase 21 trial
Active Trials
NCT02657460Unknown90Est. Dec 2019
Sandoz
SandozAustria - Kundl
1 program
1
zoledronic acidPhase 2
Biosyngen
BiosyngenSingapore - Singapore
1 program
1
BSG-001Phase 1/21 trial
Active Trials
NCT03736122Unknown58Est. Jan 2022
RS Oncology
RS OncologyMA - Cambridge
1 program
1
RSO-021Phase 1/21 trial
Active Trials
NCT05278975Unknown186Est. Apr 2025
Clover Biopharmaceuticals
Clover BiopharmaceuticalsChina - Changxing
1 program
1
SCB-313Phase 11 trial
Active Trials
NCT04123886Completed14Est. Mar 2022
Binhui Biopharmaceutical
1 program
1
Virus Activated Killer immune CellsPhase 11 trial
Active Trials
NCT05565014Unknown90Est. Jun 2024
Iovance Biotherapeutics
1 program
1
locally manufactured adoptive cellular therapyPhase 11 trial
Active Trials
NCT07192900Recruiting10Est. Dec 2037
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
locally manufactured adoptive cellular therapyPhase 1
Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
Aspira CatheterN/A1 trial
Active Trials
NCT03414905Completed40Est. Feb 2024
Rocket Pharmaceuticals
1 program
Pleural proceduresN/A1 trial
Active Trials
NCT04793607Unknown50Est. Oct 2021
Candel Therapeutics
1 program
AdV-tk + valacyclovirPHASE_1Small Molecule1 trial
Active Trials
NCT01997190Completed19Est. Feb 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AbnobaAbnoba Viscum F 20mg
UNION therapeuticstumor derived microparticles
RS OncologyRSO-021
BiosyngenBSG-001
Iovance Biotherapeuticslocally manufactured adoptive cellular therapy
Binhui BiopharmaceuticalVirus Activated Killer immune Cells
Clover BiopharmaceuticalsSCB-313
Candel TherapeuticsAdV-tk + valacyclovir
Rocket PharmaceuticalsPleural procedures
Merit MedicalAspira Catheter

Clinical Trials (10)

Total enrollment: 625 patients across 10 trials

NCT02191540AbnobaAbnoba Viscum F 20mg

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

Start: Jan 2011Est. completion: May 201368 patients
Phase 3Completed
NCT02657460UNION therapeuticstumor derived microparticles

Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion

Start: Jan 2016Est. completion: Dec 201990 patients
Phase 2Unknown
NCT05278975RS OncologyRSO-021

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Start: Mar 2022Est. completion: Apr 2025186 patients
Phase 1/2Unknown
NCT03736122BiosyngenBSG-001

A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites

Start: Jan 2019Est. completion: Jan 202258 patients
Phase 1/2Unknown
NCT07192900Iovance Biotherapeuticslocally manufactured adoptive cellular therapy

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

Start: Mar 2026Est. completion: Dec 203710 patients
Phase 1Recruiting
NCT05565014Binhui BiopharmaceuticalVirus Activated Killer immune Cells

Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

Start: Jul 2020Est. completion: Jun 202490 patients
Phase 1Unknown
NCT04123886Clover BiopharmaceuticalsSCB-313

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

Start: Jan 2020Est. completion: Mar 202214 patients
Phase 1Completed
NCT01997190Candel TherapeuticsAdV-tk + valacyclovir

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Start: Oct 2013Est. completion: Feb 201819 patients
Phase 1Completed
NCT04793607Rocket PharmaceuticalsPleural procedures

Interventions for Malignant Pleural Effusions Impact on Fatigue

Start: Sep 2020Est. completion: Oct 202150 patients
N/AUnknown
NCT03414905Merit MedicalAspira Catheter

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

Start: Jul 2018Est. completion: Feb 202440 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 625 patients
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.